Table 1 Previously reported studies on nivolumab-induced myasthenia gravis and myocarditis
No | References | Malignancy | Year | Age | Sex | Regiment | After PD-1 cycle | CPK(IU/L) | Anti-striational antibodies | Steroid | IVIG | Plasma exchange | Intubation | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Kimura et al. [15] | Melanoma | 2016 | 80 | M | Nivolumab | 1 | 9536 | Not mentioned |  +  |  +  |  +  |  −  | Improve |
2 | Fukasawa et al. [16] | Lung cancer | 2017 | 69 | F | Nivolumab | 3 | 1156 | Not mentioned |  +  |  −  |  −  | NPPV | Improve |
3 | Fazel and Jedlowski et al. [17] | Melanoma | 2019 | 78 | F | Nivolumab + Ipilimumab | ≧4 | 9198 |  +  |  +  |  +  |  +  |  −  | Death |
4 | So et al. [18] | Melanoma | 2019 | 55 | F | Nivolumab | 2 | 13,652 |  −  |  +  |  +  |  +  |  +  | Improve |
5 | Rota et al. [19] | Renal cancer | 2019 | 72 | F | Nivolumab | 1 | Not mentioned | Not mentioned |  +  |  +  |  −  |  −  | Improve |
6 | Rota et al. [19] | Renal cancer | 2019 | 71 | M | Nivolumab | 1 | Not mentioned | Not mentioned |  +  |  +  |  −  |  −  | Death |
7 | Xing et al. [20] | Lung cancer | 2020 | 66 | M | Sintilimab | 2 | 11,919 | Not mentioned |  +  |  +  |  +  |  +  | Improve |
8 | Our case | Gastric cancer | 2020 | 66 | M | Nivolumab | 1 | 8903 |  +  |  +  |  +  |  +  |  −  | Death |